

JAMA Insights

APOL1-Mediated Kidney Disease

Timothy Hopper, MD; Opeyemi A. Olabisi, MD, PhD

Introduction

According to the [United States Renal Data System 2020 Annual Data Report](#), 30% of patients with end-stage kidney disease (ESKD) in the US are Black individuals, although they comprise only 13% to 14% of the population. In 2010, researchers identified 2 common variants of the *APOL1* (apolipoprotein L1) gene (G1 and G2), which account for much of the excess nondiabetic chronic kidney disease (CKD) risk among Black individuals in the US.^{1,2} This review explains the evolutionary origin of *APOL1* high-risk genetic variants, defines APOL1-mediated kidney disease (AMKD), and discusses recommendations for AMKD screening and management.



CME at jamacmelookup.com

APOL1 and Trypanosomiasis

The wild-type *APOL1* gene (G0) was identified in 2003 as the component of human serum that confers resistance to *Trypanosoma brucei*, the cause of African trypanosomiasis (sleeping sickness). The *APOL1* gene encodes an innate immune pore-forming protein that inserts into the trypanosome's lysosomal membrane, inducing osmotic stress and ultimately lysing the trypanosome. Approximately 10 000 years ago, 2 novel *T brucei* strains emerged in Africa that were resistant to the G0 immune response and therefore caused African sleeping sickness. The G1 and G2 variants of the *APOL1* gene restored immune protection against the novel *T brucei* strains and underwent positive selection in West Africa.

Genetics of APOL1


The risk of kidney disease associated with the *APOL1* G1 and G2 alleles follows a recessive inheritance pattern. Individuals who are heterozygous for a G1 or G2 variant (G1/G0 or G2/G0) are resistant to African sleeping sickness but do not have increased risk of kidney disease. However, individuals with 2 alleles of *APOL1* G1 or G2 variants (G1/G1, G2/G2, or G1/G2) have an increased risk of kidney disease and are collectively known as the *APOL1* high-risk genotype.¹

The allele frequencies of G1 and G2 vary across different populations worldwide. The prevalence of these high-risk alleles is highest in West African populations. In different populations in Nigeria, G1 allele frequency has been reported to be 37% to 45%, and G2 frequency has been estimated to be 7.5% to 17%.² Among Black individuals in the US, the G1 allele frequency is 22% and G2 allele frequency is 13%.² Approximately 13% of Black individuals in the US (more than 5 million people) have a high-risk *APOL1* genotype.³ High-risk alleles are also found frequently in sub-Saharan African, Western African, Caribbean, Central American, and South American populations.⁴

APOL1-Mediated Kidney Disease

Recent experimental evidence suggests that the G1 and G2 variants may cause kidney injury by increased transport of monovalent

Figure. APOL1-Mediated Kidney Disease in Black Individuals in the US



Bubble plot shows the odds ratio of APOL1-mediated kidney disease (AMKD) in Black individuals in the US with a high-risk *APOL1* genotype compared with Black individuals with a low-risk *APOL1* genotype. The area of each bubble represents the population attributable risk—the proportion of the incidence of each type of kidney disease that is attributed to high-risk *APOL1* genotype.

Odds ratios from Friedman and Pollak.³ Estimated number of affected individuals was extrapolated from [United States Renal Data System](#). Population attributable risk was calculated from odds ratio and the frequency of high-risk *APOL1* genotype in the Black US population.

CKD indicates chronic kidney disease; HTN-ESKD, hypertension-attributed end-stage kidney disease; and FSGS, focal segmental glomerulosclerosis.

cations—similar to the mechanism by which G1 and G2 provide resistance to *T brucei*.^{5,6}

Individuals with a high-risk *APOL1* genotype have been estimated to have a 15% to 30% lifetime risk of developing ESKD.³ The basis of this variable penetrance is currently unknown. AMKD is diagnosed when an individual with a high-risk *APOL1* genotype develops nondiabetic kidney disease. There is no established glomerular filtration rate (GFR) cutoff to diagnose AMKD. Proteinuria (urine albumin to creatinine ratio >30 mg/g) is often present but is not a requirement for the diagnosis of AMKD.

Approximately 75% of Black individuals in the US with focal segmental glomerulosclerosis (FSGS) have been estimated to have a high-risk *APOL1* genotype.⁴ Black individuals in the US with a high-risk *APOL1* genotype are also more likely to develop hypertension-attributed ESKD, lupus nephritis-attributed ESKD, FSGS, and HIV-associated nephropathy compared with Black individuals who have a low-risk *APOL1* genotype (Figure). A recent study reported that 25.8% of patients with COVID-19-associated kidney injury had collapsing glomerulopathy, and 91.7% of these patients had a high-risk *APOL1* genotype.⁷

Screening for High-Risk APOL1 Genotype and AMKD

Screening of asymptomatic individuals in the US for high-risk *APOL1* genotype is not currently recommended. Individuals identified as

Black in clinical and epidemiological studies in the US represent a genetically diverse group, and the risk of a genetic variant is not evenly distributed in this population. However, individuals with recent West African heritage who have nondiabetic CKD, proteinuria, or a family history of kidney disease may be offered *APOL1* screening. All individuals should receive genetic counseling before and after *APOL1* genetic testing and be advised about potential for increased cost of health insurance that may be associated with detection of a high-risk *APOL1* genotype. When individuals are noted to have a high-risk genotype, physicians may consider more frequent screening for reduced GFR and proteinuria to identify AMKD at an early stage.

Prospective kidney donors with recent West African heritage may be encouraged to undergo *APOL1* genetic testing because preliminary data suggest that donors with a high-risk *APOL1* genotype have a greater decrease in postdonation kidney function and are more likely to develop ESKD. A study of 136 Black living kidney donors who were evaluated at a median of 12 years after donation reported that compared with donors with a low-risk genotype, those with a high-risk *APOL1* genotype had lower eGFR (mean [SD], 57 [18] vs 67 [15] mL/min per 1.73 m²; *P* = .02) and faster decline in eGFR after adjustment for predonation eGFR (1.19 [95% CI, 0-2.3] vs 0.4 [95% CI, 0.1-0.7 mL/min per 1.73 m² per year, *P* = .02).⁸

A study of 478 deceased donor kidney transplants from Black donors reported that after adjusted analysis, transplanted kidneys from deceased donors with a high-risk *APOL1* genotype had shorter allograft survival compared with a low-risk *APOL1* genotype (absolute rates not reported; hazard ratio, 2.05; *P* = 3 × 10⁻⁴) but no

difference in kidney recipient survival.⁹ A large ongoing National Institutes of Health–funded study, APOLLO (NCT03615235) is evaluating the effects of *APOL1* variants on outcomes for both kidney transplant donors and recipients.

Early identification of patients with a high-risk *APOL1* genotype may be associated with beneficial lifestyle modifications and decreased blood pressure. A recent study¹⁰ randomized 2050 US adults with self-identified African ancestry and hypertension without CKD to immediate vs delayed reporting (12 months later) of *APOL1* test results. At 3 months, patients identified with a high-risk *APOL1* genotype had a significantly greater decrease in mean systolic blood pressure (6 mm Hg) compared with low-risk *APOL1* genotypes (3 mm Hg) and the control group with delayed reporting (3 mm Hg). At 12 months, compared with individuals who had a low-risk genotype, patients with a high-risk *APOL1* genotype self-reported significant improvements in diet and exercise (129/218 [59%] vs 547/1468 [37%]; *P* < .01) and increased use of blood pressure medication (21/218 [10%] vs 68/1468 [5%]; *P* = .005).

Treatment Options for AMKD

Although there is currently no approved treatment for AMKD, multiple therapeutic trials are ongoing. The JUSTICE trial (NCT05237388) is testing baricitinib, a JAK-STAT inhibitor that reduces *APOL1* gene expression. A phase 2/3 clinical trial (NCT05312879) is evaluating the effect of inaxaplin, a small molecule *APOL1* inhibitor, on proteinuria and the rate of GFR decline among individuals with a high-risk *APOL1* genotype and proteinuric kidney disease.

ARTICLE INFORMATION

Author Affiliations: Division of Nephrology, Department of Medicine, Duke University School of Medicine, Durham, North Carolina (Hopper, Olabisi); Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, North Carolina (Olabisi).

Corresponding Author: Opeyemi A. Olabisi, MD, PhD, Duke Molecular Physiology Institute, Division of Nephrology, Department of Medicine, Duke University School of Medicine, 300 N Duke St, #50-104, Durham, NC 27701 (Opeyemi.Olabisi@duke.edu).

Published Online: April 25, 2024.
doi:10.1001/jama.2024.2667

Conflict of Interest Disclosures: Dr Olabisi reported grants from NIH during the conduct of the study. No other disclosures were reported.

REFERENCES

1. Genovese G, Friedman DJ, Ross MD, et al. Association of trypanolytic ApoL1 variants with

kidney disease in African Americans. *Science*. 2010; 329(5993):841-845. doi:10.1126/science.1193032

2. Kopp JB, Nelson GW, Sampath K, et al. *APOL1* genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. *J Am Soc Nephrol*. 2011;22(11):2129-2137. doi:10.1681/ASN.2011040388

3. Friedman DJ, Pollak MR. *APOL1* nephropathy: from genetics to clinical applications. *Clin J Am Soc Nephrol*. 2021;16(2):294-303. doi:10.2215/CJN.15161219

4. Nadkarni GN, Gignoux CR, Sorokin EP, et al. Worldwide frequencies of *APOL1* renal risk variants. *N Engl J Med*. 2018;379(26):2571-2572. doi:10.1056/NEJMc1800748

5. Egbuna O, Zimmerman B, Manos G, et al; VX19-147-101 Study Group. Inaxaplin for proteinuric kidney disease in persons with two *APOL1* variants. *N Engl J Med*. 2023;388(11):969-979. doi:10.1056/NEJMoa2202396

6. Datta S, Antonio BM, Zahler NH, et al. *APOL1*-mediated monovalent cation transport contributes to *APOL1*-mediated podocytopathy in

kidney disease. *J Clin Invest*. Published online January 16, 2024:e172262. doi:10.1172/JCI172262

7. May RM, Cassol C, Hannoudi A, et al. A multi-center retrospective cohort study DEFINES the spectrum of kidney pathology in Coronavirus 2019 disease (COVID-19). *Kidney Int*. 2021;100(6):1303-1315. doi:10.1016/j.kint.2021.07.015

8. Doshi MD, Ortigosa-Goggins M, Garg AX, et al. *APOL1* genotype and renal function of black living donors. *J Am Soc Nephrol*. 2018;29(4):1309-1316. doi:10.1681/ASN.2017060658

9. Freedman BI, Pastan SO, Israni AK, et al. *APOL1* genotype and kidney transplantation outcomes from deceased African American donors. *Transplantation*. 2016;100(1):194-202. doi:10.1097/TP.0000000000000969

10. Nadkarni GN, Fei K, Ramos MA, et al. Effects of testing and disclosing ancestry-specific genetic risk for kidney failure on patients and health care professionals: a randomized clinical trial. *JAMA Netw Open*. 2022;5(3):e221048. doi:10.1001/jamanetworkopen.2022.1048